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Abstract
Background
Clinical research and drug development in orphan diseases is challenging, since
large-scale randomized studies are difficult to conduct. Formally synthesizing
the evidence is therefore of great value, yet this is rarely done in the drug
approval process. Phase III designs that make better use of phase II data can
facilitate drug development in orphan diseases.
Methods
A Bayesian meta-analytic approach is used to inform the phase III study with
phase II data. It is particularly attractive, since uncertainty of between-trial
heterogeneity can be dealt with probabilistically, which is critical if the
number of studies is small. Furthermore, it allows quantifying and discounting
the phase II data through the predictive distribution relevant for phase III. A
phase III design is proposed which uses the phase II data and considers
approval based on a phase III interim analysis. The design is illustrated with a
non-inferiority case study from an FDA approval in herpetic keratitis (an
orphan disease). Design operating characteristics are compared to those of a
traditional design, which ignores the phase II data.
Results
An analysis of the phase II data reveals good but insufficient evidence for
non-inferiority, highlighting the need for a phase III study. For the phase III
study supported by phase II data, the interim analysis is based on half of the
patients. For this design, the meta-analytic interim results are conclusive and
would justify approval. In contrast, based on the phase III data only, interim
results are inconclusive and would require further evidence.
Conclusions
To accelerate drug development for orphan diseases, innovative study designs
and appropriate methodology are needed. Taking advantage of randomized
phase II data when analyzing phase III studies looks promising because the
evidence from phase II supports informed decision making. The
implementation of the Bayesian design is straightforward with public software
such as R.
Keywords: drug development in rare diseases; phase III studies; Bayesian
statistics; meta-analysis
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Introduction
Clinical research in orphan diseases is challenging. It is often impossible or
unethical to conduct large scale randomized controlled trials, which implies
that only limited evidence is available for decision making. Also, shortcomings
in the methodological approaches to evaluate medical products in rare diseases
have been identified (e.g. Unkel et al [1]). Whilst these problems have been
recognized for some time (see Orphan Drug Act from 1983 [2]), only in the
past few years strong efforts have been made to address them. Examples
include the draft guidance by the Food and Drug Administration (FDA) for
drug development in rare diseases [3] and the latest funding scheme for rare
diseases by the European Union’s Horizon 2020 research program [4]. These
activities have led to intensified rare diseases research and drug development
by pharmaceutical companies [5].
With regards to the drug approval process, some flexibility on study designs
and endpoints has been observed for drugs with an orphan indication [6, 7].
Surprisingly, however, a formal combination of the evidence (for example a
meta-analysis) is rarely presented in approval dossiers. Typically, efficacy is
assessed based on confirmatory trials only, meaning that other evidence (such
as phase II studies) is viewed as supportive only. This poses a problem to
both, regulators in charge of approving drugs and companies developing them,
since it limits the evidence base for a quantitative assessment of the treatment
effect. Furthermore, the combination of data reveals its power particularly in
situations with limited data at hand, which is often the case for rare diseases.
These challenges call for approaches to study design and analysis that allow a
more efficient use of the available data, as stipulated e.g. in the 21st Century
Cures Act [8]. The nature of the problem lends itself to the Bayesian
approach. The usefulness of the Bayesian approach when meta-analyzing few
(small) studies has been discussed elsewhere (see Friede et al [9, 10]). Here, we
extend the idea to incorporate existing evidence for the parameter of interest,
the treatment effect corresponding to the phase III study, via a meta-analysis.
This is based on concepts discussed by Spiegelhalter et al [11], Neuenschwander
et al [12, 13], Schmidli et al [14] and some ideas in Gerss and Ko¨pcke [15].
The paper is organized as follows. We first describe the statistical
methodology, then illustrate the design using data from an FDA approved
drug, and conclude with a discussion.
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Methods
Hierarchical models
Hierarchical models (HM) are widely used when data are available from more
than one trial. The models have two components: a data model and a
parameter model. Data Yj from trial j = 1, . . . , J follow a distribution F
parameterized by trial-specific parameters θj
Yj |θj ∼ F (θj) (1)
and trial parameters θj follow a distribution G
θj |η ∼ G(η) (2)
Inference for trial parameters can be done in a classical or Bayesian way. The
simplest hierarchical model assumes (approximately) normal data. Often, the
Yj are parameter estimates rather than individual data. For this case, the
normal-normal hierarchical model (NNHM) is widely used:
Yj |θj ∼ N(θj , s2j ) (3)
and
θj |µ, τ ∼ N(µ, τ2) (4)
For fixed standard errors sj and known (assumed) τ , classical and Bayesian
conclusions for µ and trial parameters θj are the same if a non-informative
(improper) prior for µ is used. For precision (inverse-variance) weights wj ,
total precision w+, and shrinkage parameters Bj
wj =
1
s2j + τ
2
, w+ =
J∑
j=1
wj , Bj =
s2j
s2j + τ
2
(5)
the posterior distribution of µ based on Y = (Y1, . . . , YJ) is
µ|Y, τ ∼ N(
∑
wjYj/w+, 1/w+) (6)
The posterior distributions of the trial parameters θj are
θj |Y, τ ∼ N(Bj µˆ+ (1−Bj)Yj , Bj(τ2 +Bj/w+)) (7)
where µˆ is the posterior mean in (6). Classical analogues to the posterior
means and standard deviations are maximum-likelihood estimates and their
standard errors. The special cases of complete pooling and stratification arise
for τ = 0 and τ =∞, respectively.
Intermediate values of τ lead to different degrees of information sharing across
trials, with the desirable properties one expects from an approach aiming to
improve inference by borrowing information from similar trials:
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• The hierarchical model shrinks the trial estimates towards the estimate
of µ, which acts as a safeguard against over-interpreting extreme (good
or bad) trial results. Shrinkage depends on trial size and between-trial
heterogeneity. For large trials (small sj), shrinkage is small, and notable
shrinkage is only possible if τ is of small to moderate size.
• The hierarchical model improves precision. Since
Bj(τ
2 +
Bj
w+
) = s2j − s2jBj(1−
wj
w+
) (8)
the variance in (7) is always smaller than the variance s2j of Yj .
Between-trial heterogeneity
The degree of between-trial heterogeneity (standard deviation τ in (4)) for the
parameters θ1, . . . , θJ depends on the parameter scale and the outcome
standard deviation σ for one observation unit (for example one subject or one
event). Table 1 shows four typical heterogeneities and respective τ values for
σ = 2, which is often used as the reference standard deviation for normal
approximations of binomial, count, and survival data [11]. For the four
heterogeneities, Table 1 shows the range of parameter values expressed as the
ratio between the 97.5% quantile and the median; for example, τ = 1 implies a
ratio of 7.1, which is clearly large and will be rare in practice.
For the common case of few trials, the size of between-trial heterogeneity is
usually highly uncertain because τ cannot be inferred well from the data.
Therefore, it is important to use prior distributions covering plausible τ values.
Half-normal, half-Cauchy, and half-t distributions have been suggested in this
context [11, 16, 17]. For the log-risk ratios used in the application, we will
consider half-normal distributions [11] with scale parameters 0.5 and 1, which
have medians (95%-intervals) equal to 0.34 (0.016,1.12) and 0.67 (0.031,2.24),
respectively. Since τ = 1 represents large heterogeneity, both priors are weakly
informative, covering small to large heterogeneity and leaving small
probabilities to unrealistically large heterogeneities, whereby the latter prior
(with median 0.67) is rather conservative. For these priors, the 97.5% quantile
to median ratio for risk ratio (RR) trial parameters is 2.98 and 8.89,
respectively (see Appendix).
Meta-analytic-predictive (MAP) prior
When designing a new trial with parameter θ?, the predictive distribution
based on previous data Y1, . . . , YJ constitutes the prior distribution for the new
trial. This is known as the meta-analytic-predictive (MAP) prior [11, 12, 14]
θ?|Y1, . . . , YJ (9)
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For the NNHM with known τ
θ?|Y1, . . . , YJ , τ ∼ N(µˆ, τ2 + 1/w+) (10)
which follows from (7) by adding the new trial (with no data) to the model,
i.e., s? =∞ and B? = 1.
Analysis for new trial
Eventually, after the new data Y? have been observed, inference for θ? can be
done in two ways:
MAP the meta-analytic-predictive (MAP) approach formally combines the
prior (9) with Y? in a standard Bayesian way.
MAC the meta-analytic-combined (MAC) approach does not require a prior
distribution for θ?. It simply infers θ? at the end of the new trial by a
meta-analysis of historical and new data, resulting in
θ?|Y1, . . . , YJ , Y? (11)
Importantly, MAC and MAC give identical results [14]. The MAP approach
is technically more involved because MAP priors (9) do not follow standard
distributions and are typically heavy-tailed. This complicates the Bayesian
analysis with Y? at the end of the trial, which can be addressed via mixture
approximations [14]. However, even if a MAC analysis will usually be the
method of choice and easy to perform with meta-analytic software, the MAP
prior plays an important role: it quantifies prior information at the design
stage, which may be required in the trial protocol.
Effective sample sizes
In many applications, the appropriate use of prior information will lead to
smaller trials. The amount of information is ideally expressed as an equivalent
approximate prior effective sample size (ESS). In our setting we are interested
in ESS?, the prior effective sample size of the MAP prior (9). Various
approaches to ESS have been proposed [12, 18, 19, 20, 21]; they are similar in
the sense that they relate the ESS to the precision (inverse of variance) of the
prior distribution.
Here, we will use an approximate two-variances approach which requires: the
variance V? of the analysis of interest, for which the ESS? is unknown; and,
the variance V0 of a simpler analysis (e.g. a meta-analysis with τ = 0) with
known ESS0. Assuming that effective sample sizes are approximately
proportional to precisions, the ESS of interest is
ESS? = ESS0 × V0
V?
(12)
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In our case, V? will be variance of the MAP prior (9), whereas V0 will be the
one from the analysis assuming no between-trial heterogeneity (τ = 0).
Case Study
We now illustrate a design which utilizes phase II data for the design and
analysis of a phase III study. The design relies on the methodology of Section
2 and additional considerations such as practical feasibility and regulatory
requirements. Data from three phase II and one phase III trial on Zirgan
(0.15% gel) for the treatment of acute herpetic keratitis will be used in the
case study. All analyses were conducted in R [22] with the package
bayesmeta [23] (see Appendix for code).
Background
Herpetic keratitis is an inflammatory condition of the eye caused by an
outbreak of the herpes simplex virus (HSV)[24, 25]. It can have serious
consequences and remains the leading cause of corneal blindness in the
industrialized world [26, 27]. With as few as 1.5 million people affected
world-wide [28], it has been classified as an orphan indication by the FDA [29]
and the European Medical Agency [30].
In 2009, the FDA approved Zirgan for the treatment of herpetic keratitis
(dendritic ulcers) [31]. To discuss all details of the approval is beyond the
scope of this application (see the publicly available documents [32]). However,
a few points are noteworthy. Most importantly, from the files [29, 32] it
appears that approval was based on a retrospective analysis of the four
relevant studies, three phase II and one phase III study. Retrospective means
that the sponsor submitted the results of the studies after they were
conducted, rather than seeking the agency’s advice beforehand. Subsequently,
this led to discrepancies between the sponsor’s and FDA’s primary analyses,
including changes of the population, of the endpoint and from superiority to
non-inferiority.
The reasons behind this rather unusual approach to approval are not entirely
clear. One explanation may be that the original manufacturer (The´a of
France) did not intend to bring Zirgan to the US market on its own; rather, it
sold the license for the US market to Sirion Therapeutics in 2007 which then
initiated the submission. This and the fact that the clinical studies were
already conducted in the 1990s may explain why no early discussions with the
FDA took place.
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Our goal here is not to reconstruct the approval history in detail. Rather, we
will use the example to discuss an alternative, more efficient statistical
approach towards approval, based on the following design specifications in the
non-inferiority setting: cure rate at day 14 as endpoint, dendritic and
geographic ulcers as population, and an absolute non-inferiority margin of 12
percentage points. Furthermore, we will use the risk ratio (RR) to quantify
the treatment effect.
In the following, we present the evidence available at the hypothetical
end-of-phase II meeting, a potential phase III trial and approval strategy, and
the results of the actual phase III trial.
Hypothetical end-of-phase II meeting
Three randomized phase II studies [33] were conducted between April 1990
and October 1992 (Table 2). The studies were similar, with the only minor
difference being the treatment regimen in study 6. For simplicity, we assume
that this difference is not relevant for the clinical outcome.
We now turn the clock back and assume we are in the situation of an
end-of-phase II meeting. We assume that the sponsor would agree to a
non-inferiority analysis of Zirgan versus Acyclovir (the standard of care) with
the primary endpoint being cure rate at day 14. Actually, setting a
non-inferiority margin proved to be difficult. For cure rate at day 14, the FDA
determined two effect sizes M1 [34]: 14% and 18% [32]. The latter implies an
absolute non-inferiority margin of 12 percentage points when retaining one
third of the effect. We assume here that this margin had been agreed to.
At this stage, it is interesting to perform a non-inferiority analysis (Zirgan
versus Acyclovir) of the phase II data. If the evidence were overwhelming, it
would be fair to ask whether a phase III study were required, or if approval
could be granted based on the phase II data only.
Our interest is the phase III treatment effect. However, since no phase III data
are available yet, the phase III treatment effect corresponds to the predicted
treatment effect θ? from the phase II studies (see Section 2). The underlying
statistical model is the NNHM (3), (4), with study-specific estimates of the
log-risk-ratios Yj = log(RRj) and standard errors
sj =
√
1/rC − 1/nC + 1/rT − 1/nT (13)
where n and r denote the number of patients and responders. This requires a
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transformation to the risk difference scale and a sensible prior distribution for
the between-trial heterogeneity parameter τ (the prior for µ will be
non-informative).
The first point is straightforward. For a response rate pC in the control group
and a pre-defined non-inferiority margin m = pC − pT , the transformation is
given by the definition of the risk ratio; for pC = 0.9 (the assumed cure rate
for Acyclovir based on historical data) and margin m = 0.12, non-inferiority
holds if RRT :C ≥ 0.867.
For the τ prior we use τ ∼ HN(0.5), which has median 0.34 and 95% interval
(0.016;1.12). This prior is centered at moderate to substantial heterogeneity
and covers small to large heterogeneity (see Table 1). Notably, one may
perform a sensitivity analysis using a prior which favors larger between-trial
heterogeneity, e.g. τ ∼ HN(1).
The meta-analysis of the phase II data is shown in Figure 1, where the data,
study-specific (stratified) risk ratios RRj , the population mean µ and the
predicted effect θ? are shown. The reference line is drawn at the non-inferiority
margin (RRT :C = 0.867 for pC = 0.9). The posterior for τ indicates small
between-trial heterogeneity, with median 0.12 (95% interval 0.00 to 0.51).
The meta-analysis provides evidence for non-inferiority. If µ were the
parameter of interest, an almost conclusive statement would follow: the lower
bound of the 95% interval is just below the non-inferiority margin. In fact,
P (µ ≥ log(0.867)) = 97.1%, very close to 97.5%. However, the parameter θ? in
the phase III trial is of interest. For this parameter, the evidence for
non-inferiority is weaker, but still substantial: P (θ? ≥ log(0.867)) = 92.0%.
Phase III study and proposed strategy for approval
Designing a phase III study that allows to assess non-inferiority in
combination with the available evidence is desirable. Not only will this allow
to run a smaller study, it will also provide a treatment effect estimate based on
all relevant evidence. However, regulators may have good reasons to argue
that a smaller study may provide insufficient information for approval,
especially to assess the safety and risk/benefit ratio.
We now discuss the design of a phase III study (study 7) which uses phase II
data and allows for seeking approval based on an interim analysis. Depending
on negotiations with regulators, a post-approval commitment to run the study
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to its end (even if approval is granted at interim) may be required. However,
such negotiations will always be case-specific, highlighting the importance of
early discussions with regulators. Nevertheless, the option to seek approval
based on a positive interim analysis seems attractive for this case study. Since
the endpoint is evaluated at day 14, there will be a small time window
between the last patient enrolled for the interim analysis and the actual data
read-out and analysis. With an anticipated recruitment period of two years,
such a strategy could result in a markedly earlier approval.
When seeking approval based on interim results, the information fraction for
the interim analysis becomes a key design aspect. We will assume that the
interim analysis is conducted after 50% of the patients have been evaluated.
For the sample size, in order to align with the actual study as originally
conducted, we will assume nC = nT = 80. This results in interim sample sizes
n˜C = n˜T = 40.
It is also important to understand how much phase II information is borrowed
(which depends on the between-trial heterogeneity) when inferring the phase
III effect. Using the variance ratio approach (Section 2), the ESS is 14.
Operating characteristics
We evaluate the operating characteristics (type I error rate and power) of the
design and compare them to a phase III design ignoring the phase II data.
The operating characteristics are presented in Table 3 based on 10’000
simulations conducted in R [22] with the package bayesmeta [23]. For different
response rates pC and treatment differences δ, two probabilities are shown: the
probability to be successful at the final analysis (regardless of the outcome of
the interim analysis), and the probability to be successful both at the interim
and the final analysis.
The gain in power for the proposed design can be substantial. For example,
for pC = 0.7 (the Acyclorivr cure rate observed in phase II) and δ = 0.06, the
power is 87% versus 66%. The power gain is even larger at interim (70%
versus 35%). When pC = 0.9 (the observed cure rate for Acyclovir based on
historical data) and δ = 0, the power is 87% versus 79%, and 68% versus 48%
at interim. The larger increase in power at interim is remarkable and due to
the highly consistent phase II results, which suggested superiority of Zirgan.
The gain in power, however, comes at the price of an increased type I error
rate. Strict type I error rate control cannot be guaranteed [35]. For example,
for pC = 0.7 and pC = 0.9, the type I error rates are 6% versus 1% and 8%
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versus 3%. This increase is not dramatic, yet it cannot be ignored and needs
to be discussed with regulators during the design phase. If it is of concern,
robust prior distributions could be considered [14].
Actual phase III data and analysis
The actual data observed in the phase III study are only available for the final
analysis. In order to reconstruct an interim analysis using half of the patients,
we use an interim sample size of 40 per arm. Furthermore, we choose the
number of responders such that observed response rate at interim is close to
the observed response rate at the final analysis (see Figure 2).
The results are presented in Figure 2. The interim analysis based on all data
(meta-analysis) allows to declare non-inferiority. Note that non-inferiority is
claimed based on the parameter corresponding to study 7 (θ?) incorporating
the evidence from studies 4, 5 and 6. On the other hand, the evidence from
the phase III study alone is insufficient to declare non-inferiority at interim
because the 95% interval includes the non-inferiority margin.
As mentioned before, the idea would be to gain approval with the interim
phase III data supported by phase II via the meta-analysis, assuming other
data (such as safety) is also favorable. Yet, depending on negotiations with
regulators, the study may still run to its end, allowing a more robust
evaluation of the effect at the final analysis. The results for the final analysis
are also shown in Figure 2. For the meta-analysis, the interval for the risk
ratio becomes narrower and still excludes the non-inferiority margin, thus
confirming the interim result. The analysis using the phase III study leads to a
lower bound of the interval (0.870) which is just above the non-inferiority
threshold 0.867, also allowing to conclude non-inferiority.
Finally, results for τ indicate small between-trial heterogeneity at the interim
and the final analysis. The posterior median (95% interval) is 0.12 (0.00 to
0.41) for the interim and 0.13 (0.00 to 0.43) for the final analysis. This
supports the consistency of the results across all studies.
Discussion
Here we presented a simple, yet attractive design in rare diseases using phase
II data in phase III studies. We illustrated it for binary endpoints, but the
extension to other endpoints is straightforward.
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The proposed approach uses the phase II data prospectively, which has
obvious advantages. First, fewer patients are required in the phase III study.
Second, the estimate combines all available evidence. And third, due to the
nature of the approach, extreme results will be pulled towards the population
mean. The Zirgan case study used to illustrate the design is built on real data
as submitted to the FDA. However, the FDA approved Zirgan for a different
indication (dendritic ulcers only) and endpoint (cure rate at day 7) than those
used in our case study.
Of course, as with any design, all stakeholders need to be convinced. It may
be argued that the case study is quite atypical since phase II studies are often
not randomized in orphan diseases. This, however, becomes a self-fulfilling
prophecy: if evidence from randomized phase II studies is only considered
supportive, there is little motivation to perform them. On the other hand, if
data from randomized phase II studies could be used, this would make them
more attractive. It is therefore important that patient groups, regulators and
sponsors consider such designs.
Other designs have been proposed before, and an excellent overview is given in
Korn et al [36]. Some have been implemented in practice, for example the
historical control monotherapy design proposed by French et al [37]. This
design was used successfully, resulting in the approval of Aptiom
(eslicarbazepine acetate) for the treatment of partial-onset seizures [38, 39].
Other examples include N-of-1 trials [40], global studies [41], or basket trials,
e.g. the B2225 study for Imatinib [42].
It is also worth mentioning that recent initiatives to improve the drug
development process send encouraging signals that a better use of the evidence
is welcomed. Important directions are given in the 21st Century Cures Act [8],
which encourages the FDA to further evaluate the use of Bayesian
methodology and non-randomized evidence. Furthermore, calls have been
made to make the drug approval process more continuous and flexible to
account for evidence as it accumulates [43]. The European Medicines Agency
has also initiated various working groups.
It is clear that we only considered a small portion of the drug approval
process. Efficacy plays a unique role when seeking approval, but other
measures are also important. Safety is critical, and additional evidence may be
required to assess long-term risks. However, this can often be achieved as a
post-approval requirement in the form of non-randomized open-label studies.
This approach has the advantage that patients have early access to the
treatment whilst additional data are collected.
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The proposed approach has limitations. The potential increase in type I error
needs to be considered and may require design modifications, including robust
meta-analytic models [14]. Likewise, for a non-inferiority design, one may
consider to directly model the risk difference and use a meta-analytic approach
on this scale (e.g. Warn et al [44]). However, most applications will be
superiority trials, for which relative measures such as risk ratios or odds ratios
are common. Finally, we did not use historical data to inform the prior for the
between-trial heterogeneity (τ), even though this would be possible [45].
The motivation of this paper was not to challenge FDA’s decision. On the
contrary: only due to the many publicly available FDA documents, we were
able to use this insightful example. We hope that it will facilitate the
implementation of the proposed design in practice.
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Tables
Table 1: Classification of between-trial heterogeneity with 97.5% quantile to
median ratio for risk ratio (RR) trial parameters; σ is the outcome standard
deviation, τ is the between-trial standard deviation.
heterogeneity (σ/τ) τ (if σ = 2) RR97.5%/RR50%
large (2) 1 7.10
substantial (4) 0.5 2.66
moderate (8) 0.25 1.63
small (16) 0.125 1.28
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Table 3: Operating characteristics for phase II/III (meta-analysis) and phase
III alone
δ = pT − pC
pC -0.12 -0.06 0.0 0.06 0.12
0.70 6 (3) 25 (15) 56 (39) 87 (70) 98 (90)
1 (0) 8 (3) 30 (12) 66 (35) 93 (67)
0.75 7 (4) 26 (16) 61 (44) 91 (75) 100 (94)
1 (0) 10 (4) 36 (16) 76 (44) 98 (78)
0.80 7 (4) 29 (18) 68 (49) 94 (80) 100 (97)
2 (1) 13 (5) 46 (22) 87 (57) 100 (90)
0.85 7 (4) 32 (19) 76 (55) 98 (88) 100 (100)
3 (1) 17 (7) 60 (31) 95 (72) 100 (99)
0.90 8 (4) 38 (24) 87 (68) 100 (98) –
3 (1) 26 (11) 79 (48) 100 (94) –
Percentages presented: probability for success at final
(probability for success at interim and final). The first
row corresponds to the meta-analysis, the second row to
the analysis of the phase III study alone.
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Figures
Figure 1: Data and results at end-of-phase II meeting
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Figure 2: Data and results for interim and final analysis in Phase III
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Appendix
library("bayesmeta")
library("metafor")
################################################
# Part I - ratio of RRs for tau ~ HN(...)
################################################
set.seed(314)
N <- 1000000
tau1 <- abs(rnorm(N, 0, 0.5))
tau2 <- abs(rnorm(N, 0, 1.0))
theta1 <- rnorm(N, 0, tau1)
theta2 <- rnorm(N, 0, tau2)
exp(quantile(theta1, prob = 0.975))
exp(quantile(theta2, prob = 0.975))
################################################
# Part II - application
################################################
# --------------------------------------------
# read-in data
# transform into 2x2 cell entries
# derive mean and se from normal approximation
# --------------------------------------------
all.data <- data.frame(study = c("4", "5", "6", "7IA", "7FA"),
rt = c(19, 15, 31, 35, 74),
nt = c(23, 18, 36, 40, 84),
rc = c(16, 12, 27, 36, 73),
nc = c(22, 17, 38, 40, 80))
all.data$ai <- all.data$rt
all.data$bi <- all.data$nt - all.data$rt
all.data$ci <- all.data$rc
all.data$di <- all.data$nc - all.data$rc
nmappr <- escalc(ai=ai, bi=bi, ci=ci, di=di,
data=all.data,measure="RR")
# --------------------------------------------------
# analyses:
# - end-of-phase-II
# - interim for phase III
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# - final for phase III
# summaries:
# - population mean,
# - predicted effect for end-of-phase-II
# - phase-III effect for interim and final analyses
# --------------------------------------------------
eop2 <- bayesmeta(y = nmappr$yi[1:3], sigma = sqrt(nmappr$vi[1:3]),
tau.prior = function(t){dhalfnormal(t,scale=0.5)})
ph3IA <- bayesmeta(y = nmappr$yi[1:4], sigma = sqrt(nmappr$vi[1:4]),
tau.prior = function(t){dhalfnormal(t,scale=0.5)})
ph3FA <- bayesmeta(y = nmappr$yi[c(1:3,5)], sigma = sqrt(nmappr$vi[c(1:3,5)]),
tau.prior = function(t){dhalfnormal(t,scale=0.5)})
round(exp(t(eop2$summary)[,c("median", "95% lower", "95% upper")]), 3)
round(exp(ph3IA$theta[c("median", "95% lower", "95% upper"),4]), 3)
round(exp(ph3FA$theta[c("median", "95% lower", "95% upper"),4]), 3)
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